259.76
-0.75%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kopran
Its shares trade on NSE under the ticker KOPRAN.NS. It has been listed since 17 November 1992. In the fiscal year to 31 March 2025, it reported revenue of ₹6.30bn and net income of ₹385.5m. At that date it held total assets of ₹8.44bn and shareholders' equity of ₹5.18bn.
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The firm's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. The company provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The firm's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Nov 1992
- Employees
- 394
- Website
- kopran.com ↗
Leadership
Pay as last reported
- Shri. Susheel SomaniNon-Executive Chairman of the Board₹60,000
- Shri. Surendra SomaniExecutive Vice Chairman of the Board, since 2019₹3.0m
- Mr. Basant SoniChief Financial Officer
- Mr. Sunil SodhaniCompliance Officer, Company Secretary
- Mr. Adarsh SomaniAdditional Non-Executive Director, since 2006₹75,000
- Mr. Varun SomaniAdditional Non-Executive Director₹85,000
- Mr. Narayan AtalNon-Executive Independent Director₹92,000
- Mrs. Mamta BiyaniNon-Executive Independent Director₹102,000
- Ms. Chandni ShahInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kopran Ltd. manufactures penicillin-based and non-penicillin-based formulations in Mumbai, India.
- The company produces APIs including anti-hypertensive, macrolides, and sterile carbapenems.
- Kopran Ltd. offers a wide range of pharmaceutical products like capsules, injectables, and tablets.
Weaknesses
- Kopran Ltd. has only 394 employees in the Mumbai headquarters.
- The company focuses solely on pharmaceutical manufacturing without diversification.
- Kopran Ltd. does not mention any international markets or exports.
Opportunities
- Kopran Ltd. can expand into the growing Indian pharmaceutical market.
- The company could leverage its API production for global supply chains.
- Kopran Ltd. may develop new formulations in cardiovascular and anti-diabetic segments.
Threats
- Kopran Ltd. faces competition from larger Indian pharmaceutical firms.
- The Indian pharmaceutical sector has strict regulatory requirements.
- Kopran Ltd. might encounter supply chain disruptions in Mumbai.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.